Defend 400 Reduces MRSA Surrogate
Objective
To evaluate the efficacy of the Defend 400 at reducing aerosolized Staphylococcus epidermidis, a surrogate for Staphylococcus aureus, MRSAand Micrococcus luteus. MRSA is a known superbug.
Methodology
The environmental chamber used for this study was 30m3 in size and designed to replicate a room setting.
The bio-aerosol was generated using a 24-jet Collison nebuliser operated with a purified filtered air supply.
The bio-aerosol samples were collected at 15-minute intervals in sterile SKC BioSampler impingers to determine the chamber concentration.
Summary of Results
The Defend 400 achieved greater than a log-4 reduction (>99.99%) of Staphylococcus epidermidis after 45 minutes.
